drugset
drugset / Trial / NCT05808634

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

NCT05808634 ↗

Phase 1 Recruiting 168 enrolled BioAtla, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma

Timeline

Start
2023-07-14
Primary completion
2028-09-15
Completion
2028-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject BA3182 Unknown — —

Indications

adenocarcinoma